rs587776596
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_031433.4(MFRP):βc.498delβ(p.Asn167ThrfsTer25) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000075 in 1,613,826 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.00012 ( 0 hom., cov: 33)
Exomes π: 0.000070 ( 0 hom. )
Consequence
MFRP
NM_031433.4 frameshift
NM_031433.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 1.33
Genes affected
MFRP (HGNC:18121): (membrane frizzled-related protein) This gene encodes a member of the frizzled-related protein family. The encoded protein plays an important role in eye development and mutations in this gene have been associated with nanophthalmos, posterior microphthalmia, retinitis pigmentosa, foveoschisis, and optic disc drusen. The protein is encoded by a bicistronic transcript which also encodes C1q and tumor necrosis factor related protein 5 (C1QTNF5). [provided by RefSeq, Jun 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-119345562-TG-T is Pathogenic according to our data. Variant chr11-119345562-TG-T is described in ClinVar as [Pathogenic]. Clinvar id is 4476.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-119345562-TG-T is described in Lovd as [Pathogenic]. Variant chr11-119345562-TG-T is described in Lovd as [Likely_pathogenic]. Variant chr11-119345562-TG-T is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MFRP | NM_031433.4 | c.498del | p.Asn167ThrfsTer25 | frameshift_variant | 5/15 | ENST00000619721.6 | NP_113621.1 | |
C1QTNF5 | NM_015645.5 | c.-2139del | 5_prime_UTR_variant | 5/15 | NP_056460.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MFRP | ENST00000619721.6 | c.498del | p.Asn167ThrfsTer25 | frameshift_variant | 5/15 | 1 | NM_031433.4 | ENSP00000481824 | P1 | |
MFRP | ENST00000360167.4 | c.498del | p.Asn167ThrfsTer25 | frameshift_variant | 5/10 | 2 | ENSP00000353291 | |||
MFRP | ENST00000529147.2 | n.461del | non_coding_transcript_exon_variant | 4/6 | 5 | |||||
MFRP | ENST00000634542.1 | c.*89del | 3_prime_UTR_variant, NMD_transcript_variant | 4/5 | 3 | ENSP00000488979 |
Frequencies
GnomAD3 genomes AF: 0.000125 AC: 19AN: 152022Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
19
AN:
152022
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000129 AC: 32AN: 248178Hom.: 0 AF XY: 0.000119 AC XY: 16AN XY: 134620
GnomAD3 exomes
AF:
AC:
32
AN:
248178
Hom.:
AF XY:
AC XY:
16
AN XY:
134620
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000698 AC: 102AN: 1461686Hom.: 0 Cov.: 57 AF XY: 0.0000633 AC XY: 46AN XY: 727136
GnomAD4 exome
AF:
AC:
102
AN:
1461686
Hom.:
Cov.:
57
AF XY:
AC XY:
46
AN XY:
727136
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000125 AC: 19AN: 152140Hom.: 0 Cov.: 33 AF XY: 0.000121 AC XY: 9AN XY: 74370
GnomAD4 genome
AF:
AC:
19
AN:
152140
Hom.:
Cov.:
33
AF XY:
AC XY:
9
AN XY:
74370
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Nanophthalmos 2 Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2012 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Isolated microphthalmia 5 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 13, 2023 | This sequence change creates a premature translational stop signal (p.Asn167Thrfs*25) in the MFRP gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MFRP are known to be pathogenic (PMID: 12140190, 15976030, 20361016). This variant is present in population databases (rs587776596, gnomAD 0.04%). This premature translational stop signal has been observed in individuals with posterior microphthalmos/nanophthalmos and retinal dystrophy in a family, and has been observed in several affected individuals (PMID: 19753314, 23112574, 23143909). It has also been observed to segregate with disease in related individuals. This variant is also known as c.492delC, p.P166fs*26, and p.P166fs*190. ClinVar contains an entry for this variant (Variation ID: 4476). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2012 | - - |
not provided Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
MFRP-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 22, 2024 | The MFRP c.498delC variant is predicted to result in a frameshift and premature protein termination (p.Pro166Profs*26). This variant has been reported in the homozygous and compound heterozygous states in individuals with nanophthalmos or retinal dystrophy (reported as 492delC in Sundin et al. 2005. PubMed ID: 15976030; Kannabiran et al. 2012. PubMed ID: 22605927; Guo et al. 2019. PubMed ID: 31266062; Prasov et al. 2020. PubMed ID: 33203948). This variant is reported in 0.042% of alleles in individuals of Latino descent in gnomAD. Frameshift variants in MFRP are expected to be pathogenic, and this variant has been classified as pathogenic by multiple independent submitters to the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/4476). Given the evidence, we interpret this variant as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at